Edwards Lifesciences Corp. (NASDAQ: EW) Chief Executive Officer Bernard J. Zovighian executed a transaction to sell 523 shares of the company's common stock on June 17, 2026. According to a recent Securities and Exchange Commission filing, the total value of the sale was $45,982. The transaction was carried out at a price of $87.92 per share. The disposal of these shares was executed indirectly through a trust mechanism. This sale was facilitated under a Rule 10b5-1 trading plan, which Mr. Zovighian adopted on December 12, 2025.
Following the completion of this transaction, Mr. Zovighian's indirect ownership through the trust has been reduced to 11,516.5511 shares. His direct holdings remain at 99,164.6499 shares of common stock. Furthermore, he maintains an indirect holding of 3,733.5603 shares through a 401(k) plan. The execution of this sale coincides with Edwards Lifesciences stock trading near its 52-week high of $89.60. As of the latest trading data, the shares are valued at $86.68. According to InvestingPro analysis, the stock appears slightly overvalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive Pro Research Reports and additional ProTips on InvestingPro, covering this and 1,400+ other US equities.
Edwards Lifesciences recently reported its financial results for the first quarter of 2026. The company achieved revenue of $1.65 billion, representing a 12.7% increase from the previous year on a constant currency basis. The company also reported earnings per share of $0.78, which marks a 22% rise year-over-year. This performance surpassed both Street estimates and company guidance.
In response to these results, TD Cowen reiterated its Buy rating on Edwards Lifesciences. The firm maintained a $97.00 price target following the strong results. Additionally, TD Cowen raised its price target to $104. This adjustment cites expected market share gains in the transcatheter aortic valve replacement (TAVR) sector and potential double-digit top-line growth.
Edwards Lifesciences received a positive response after the U.S. government proposed a National Coverage Decision memo for TAVR. The memo included several relaxed restrictions. Analysts from Leerink reiterated a Market Perform rating, expressing an incrementally positive view on the company following this development.
The company also announced the appointment of Theodora Mistras as the new chief financial officer. Her appointment is effective at the end of May, and she succeeds Scott Ullem. These developments highlight the ongoing strategic and financial progress at Edwards Lifesciences.
Should you invest $2,000 in EW right now? ProPicks AI evaluates EW alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if EW is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?